

## Professor Olle Hernell has received the Macy György award

**Press release: Umeå, 19 August, 2021. Professor Olle Hernell that is co-founder and board member of Lipum has been honored with the Macy György award 2021 for his research in human milk and lactation.**

For almost 50 years Professor of Pediatrics Olle Hernell and his group at Umeå University have been studying breast milk and its importance for nutrition of newborns during early infancy with focus on the bioactive protein that is now known as bile salt-stimulated lipase (BSSL). Hernell and his team also revealed that BSSL plays a role in inflammation and is present in human granulocytes, a type of white blood cells. This novel finding redirected the focus of their research to studies on BSSL in inflammatory processes and, eventually, lead to the development of Lipum's antibody and candidate drug SOL-116.

The Macy György award honors individuals who have made outstanding and internationally recognized scientific contributions to the study of human milk and lactation. The Executive Committee of the [International Society for Research in Human Milk and Lactation](#) has honored investigators in the field since 1995.

Professor Olle Hernell received the award "for outstanding lifetime achievement in scientific contributions to the study of human milk and lactation" during the International Society for Research in Human Milk and Lactation conference held August 16-20, 2021.

"It is a strength with Lipum's high scientific level and we congratulate Professor Hernell for the recognition of his scientific contributions", says Einar Pontén CEO at Lipum.

### **For further information, please contact:**

Einar Pontén, CEO

E-post: [ainar.ponten@lipum.se](mailto:ainar.ponten@lipum.se)

Mobile: +46 70 5783495

Web: [www.lipum.se](http://www.lipum.se)

### **About Lipum**

Lipum AB (publ) is a biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in late preclinical stage supported by solid data for the rare disease juvenile idiopathic arthritis and rheumatoid arthritis. Lipum also explores several other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum's unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission, email: [ca@gwkapital.se](mailto:ca@gwkapital.se), phone: +46 8 503 000 50.